Seth Lederman Purchases 5,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman purchased 5,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The shares were bought at an average cost of $11.79 per share, with a total value of $58,950.00. Following the acquisition, the chief executive officer directly owned 9,005 shares of the company’s stock, valued at $106,168.95. This trade represents a 124.84% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Seth Lederman also recently made the following trade(s):

• On Wednesday, March 18th, Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $14.89 per share, with a total value of $223,350.00.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ TNXP traded down $0.25 during mid-day trading on Tuesday, reaching $11.46. The company’s stock had a trading volume of 544,959 shares, compared to its average volume of 425,927. The firm has a market capitalization of $182.68 million, a PE ratio of -0.80 and a beta of 1.67. The stock has a fifty day moving average of $13.20 and a two-hundred day moving average of $15.06. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $10.87 and a 52 week high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Monday, May 11th. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). The business had revenue of $6.88 million during the quarter, compared to the consensus estimate of $6.13 million. Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%. Analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -9.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TNXP. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. TD Cowen raised Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. Finally, Wall Street Zen lowered Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors have recently modified their holdings of TNXP. Royal Bank of Canada bought a new stake in shares of Tonix Pharmaceuticals in the 1st quarter valued at approximately $610,000. Geode Capital Management LLC lifted its stake in shares of Tonix Pharmaceuticals by 182.4% in the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock valued at $6,305,000 after purchasing an additional 113,175 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at approximately $129,000. Legal & General Group Plc bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at approximately $25,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at approximately $104,000. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.